Summary of results for people diagnosed with kidney cancer in England (2018-2022) and Wales (2022-2023)



Diagnosis & staging (England 2020-2022 and Wales 2022-2023)

England in 2020-2022 Wales in 2022-2023 **28,485 986**

people were diagnosed with **kidney cancer**

59% E 47% w of people with kidney cancer were diagnosed at stage T1 and any N/M category

69 years

age at diagnosis (median) Interquartile range **59 - 77 years**

64%

of people were male

21% E 23% w of people had metastastatic disease (M1)



The number within the circle represents the national percentage (England top: Wales bottom) for the time period indicated

82% E 99% w of people with kidney cancer who had a record of being discussed at a multidisciplinary team (MDT) meeting




1%

of people with kidney cancer had **consented for a clinical trial**

Data unavailable for Wales

Treatment Allocation (England 2020-2022)



68%

of people with a T3+ and/or 10cm+ and/ or N1 and M0 renal cell carcinoma (RCC) had radical nephrectomy within 31 days of decision to treat

63% in 2022 **69%** in 2021 **73%** in 2020 (3)

Data unavailable for Wales

Surgery (England 2020-2022 and Wales 2022-2023)



of people with T1b-3NXM0 RCC underwent surgery 1 month prior and 12 months following diagnosis in England

78% in 2022 **78%** in 2021 **76%** in 2020

82%

22222

of people with T23NXM0 RCC **underwent surgery** 1 month prior and 12 months following diagnosis in Wales

84% in 2023 **80%** in 2022

69%

22222

of people with T1aN0M0 underwent nephron sparing treatment 1 month prior and 12 months following diagnosis in England

70% in 2022 **72%** in 2021 **66%** in 2020

Data unavailable for Wales

Systemic Anti-Cancer Therapy (SACT, England 2018-2022 and Wales 2022-2023)

49% E 54% w

England

of people with metastatic RCC received initial SACT within 12 months of diagnosis

50% in 2022 **52%** in 2021 **48%** in 2020

Wales

53% in 2023 **56%** in 2022

3% E 2% w

of people with kidney cancer died within 30 days of SACT treatment

England **4%** in 2022 **3%** in 2021

3% in 2021 **2%** in 2020 Wales 0

0% in 2023 **3%** in 2022

T3+ and/or 10cm+ and/or N1 and M0 RCC - Tumour extends into major veins or perinephric tissues or invades beyond Gerota fascia and/or tumour more than 10cm in size and/or metastasis in regional lymph node(s)

T1b-3NXM0 RCC - Tumour is more than 4cm in size or tumour extends into major veins or perinephric tissues with no distant metastasis

T1aNOMO RCC - Tumour is less than or equal to 4cm in size with no regional lymph node metastasis and no distant metastasis